Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease.

Pharmacoepidemiology and Drug Safety
Naomi P VisanjiConnie Marras

Abstract

Drug repurposing is an effective means of increasing treatment options for diseases, however identifying candidate molecules for the indication of interest from the thousands of approved drugs is challenging. We have performed a computational analysis of published literature to rank existing drugs according to predicted ability to reduce alpha synuclein (aSyn) oligomerization and analyzed real-world data to investigate the association between exposure to highly ranked drugs and PD. Using IBM Watson for Drug Discoveryâ (WDD) we identified several antihypertensive drugs that may reduce aSyn oligomerization. Using IBM MarketScanâ Research Databases we constructed a cohort of individuals with incident hypertension. We conducted univariate and multivariate Cox proportional hazard analyses (HR) with exposure as a time-dependent covariate. Diuretics were used as the referent group. Age at hypertension diagnosis, sex, and several comorbidities were included in multivariate analyses. Multivariate results revealed inverse associations for time to PD diagnosis with exposure to the combination of the combination of angiotensin receptor II blockers (ARBs) and dihydropyridine calcium channel blockers (DHP-CCB) (HR = 0.55, p < 0.01) and angio...Continue Reading

References

Jun 1, 1992·Journal of Clinical Epidemiology·R A DeyoM A Ciol
Oct 15, 1995·Journal of Neuroscience Research·T FukushimaY Yamane
Aug 28, 1997·Nature·M G SpillantiniM Goedert
Dec 25, 2002·Neurobiology of Aging·Heiko BraakEva Braak
May 25, 2005·Brain Research·Tom N GrammatopoulosW Michael Zawada
Jun 15, 2007·Nature·C Savio ChanD James Surmeier
Feb 8, 2008·Neurology·Claudia BeckerChristoph R Meier
Apr 10, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·G R K SarmaA K Roy
May 24, 2008·Neurobiology of Disease·J Rodriguez-PallaresJ L Labandeira-Garcia
Aug 22, 2009·Neuroepidemiology·Elan D LouisUNKNOWN Neurological Disorders in Central Spain (NEDICES) Study Group
Nov 26, 2009·The Journal of Pharmacology and Experimental Therapeutics·Preeti PutchaPamela J McLean
May 4, 2010·Annals of Neurology·Beate RitzSøren Friis
Sep 30, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Karin M DanzerPamela J McLean
May 10, 2011·International Urology and Nephrology·Lehana YeoJunaid Masood
Jun 2, 2011·Nature Reviews. Drug Discovery·Fabio PammolliMassimo Riccaboni
Feb 23, 2012·Cold Spring Harbor Perspectives in Medicine·Leonidas Stefanis
Mar 2, 2012·Nature Reviews. Drug Discovery·Jack W ScannellBrian Warrington
Mar 28, 2012·Annals of Neurology·Connie MarrasPeter C Austin
Nov 28, 2012·Nature Reviews. Neurology·Michel GoedertHeiko Braak
Apr 2, 2014·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Yusuke FukuiKoji Abe
May 2, 2014·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Kota SatoKoji Abe
Jul 1, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Tamara PringsheimThomas D L Steeves
Dec 5, 2014·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Sarah-Ann AelvoetVeerle Baekelandt
Mar 19, 2015·Expert Opinion on Therapeutic Targets·Simon MoussaudPamela J McLean
May 29, 2015·Journal of Neurochemistry·Ryoichi TakahashiMasahito Yamada
Aug 15, 2015·The Journal of Pharmacology and Experimental Therapeutics·Sarah E LacherErica L Woodahl
Jun 17, 2016·Nature·Nicola Nosengo
Jul 28, 2016·Proceedings of the National Academy of Sciences of the United States of America·Timothy S JarvelaIris Lindberg
Mar 5, 2017·Gait & Posture·Alice LaudisioGiuseppe Zuccalà
Mar 24, 2017·Nature Reviews. Disease Primers·Werner PoeweAnthony E Lang
Aug 25, 2017·Expert Opinion on Investigational Drugs·Santiago Perez-LloretFrancisco Capani
Jun 17, 2018·Neuropharmacology·Tom H JohnstonJonathan M Brotchie
Jul 11, 2018·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ana I Rodriguez-PerezJose L Labandeira-Garcia
Aug 21, 2019·International Journal of Clinical Pharmacology and Therapeutics·Ahmed WardaKarel Kostev

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Related Papers

The Journal of the Association of Physicians of India
K S Reddy, D Prabhakaran
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
Walid F Gellad, C Bernie Good
© 2021 Meta ULC. All rights reserved